I think you're referencing
The 5/30/24 Webcast where Scott Hansen, PhD actually spoke:
The 5/30/24 Webcast where Scott Hansen, PhD actually spoke:
Quote:" The First Data I analyzed from this trial, I was instantly amazed how leronlimab was changing the immune cell landscape in treated patients. The mouse immunologists like to call these changes: Macrophage polarization. But what I was observing was much more nuanced and robust. I was observing near complete Immune modulation, almost all major immune cell classes, including T and B cells, not just macrophage polarization. And after making this observation, I knew from that day that this molecule could be useful as a therapeutic including treatment for various cancers and neuroinflammatory disorders.
So, when Cyrus Arman asked me to join the company in a more formal capacity, it was very easy for me to say, yes. As I said earlier, I believe this molecule can help and will help people. But enough about me, I think what most people are interested in hearing about is what we've been up to this past year.
Scott Hansen 22:18:
I'm delighted to say that the Personnel additions Tanya and the board have made to the company, in my opinion, have been amazing. We all work super well together and because of this, we were finally able to get leronlimab off the clinical hold, but more importantly, for the sake of getting leronlimab into the people where it should be for the first time, Jay and Cyrus greenlighted, a deep dive into the data from our past clinical trials.
I think you heard Jay speak of this a little earlier of re-analyzing the Nash data. This is part of that. You may ask why that is so important. Well, I believe we are currently making sound and up-to-date plans based off our actual clinical data and we have lots of it. And we're using these data to drive our decisions of where we feel Leronlimab can be most impactful which hopefully will equate to the quickest path to approval and viable partnerships. I think Jay did a great job, outlining CytoDyn's future and why we are devoting our resources to these specific areas, and I can confidently tell you those decisions were based off of actual data from our trials, compensation from statisticians reviewing that data and expert opinions from the scientific community, and the work that I've done in the lab related to the mechanism of action. We have lots of data in the lab now. Finally, I'm very excited to share with you some exciting things happening in our pre-clinical programs.
Scott Hansen 23:41: 17 variants of leronlimab
First and I think Jay concluded his first section of his talk on this is to protect and expand our IP portfolio. We are working with a local generative AI company to design and create not only a longer lasting leronlimab, but possibly a more potent molecule that can be used in pre-exposure prophylaxis or PREP. A space where we think in combination with a long-acting antiretroviral, will have huge impacts for the HIV community.
I'm currently testing 17 new variants of leronlimab. It's really early in this process, but some of these new molecules are showing extreme promise in my in-vitro assays. I'm making sure that the function of leronlimab is not altered, but preserved, and these data are very exciting and yet very, very early, but very promising.
I'm very excited about this endeavor and I feel it will be a game changer for CytoDyn and will help preserve the company's future. Lastly, I feel another game changer for CytoDyn, is the LATCH trial Jay mentioned earlier in his presentation. This is something very exciting for us as a company and me, personally, I became a scientist, not only to move science forward, but to also to try to save life, Dr. Jonah Sasha's work with leronlimab and stem cell transplant in the non-human primate model really made this trial possible for us. He demonstrated that you can pharmacologically knock out CCR5 with leronlimab, essentially creating that Delta 32 phenotype that Jay mentioned. The phenotype has facilitated HIV CURE in the setting of stem cell transplantation.
Obviously, this isn't a therapy for everyone living with HIV, but for those that it makes sense for, we believe leronlimab can help cure people of HIV and that would be pretty remarkable and something we can all be very proud of. I can go on and on about my excitement about this molecule, but for the sake of time, I'm going to hand the mic back over to Jay.
Thank you for listening to me today. It was my pleasure to be here, and I'm happy to be part of all this. "
16
